ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME

被引：0
|
作者：
Merchan, B. [1 ]
Ortega, M. [2 ]
Llamas-Poyato, M. J. [3 ]
Cortes, M. [4 ]
Arnan, M. [5 ]
Cervero, C. [6 ]
Montoro, J. [1 ]
Gimenez, T. [7 ]
Lopez, M. [8 ]
Arenillas, L. [9 ]
Valcarcel, D. [1 ]
机构：
[1] Hosp Valle De Hebron, Hematol, Barcelona, Spain
[2] Hosp Valle De Hebron, Hematol Cytogenet Lab, Barcelona, Spain
[3] Hosp Reina Sofia, Hematol, Cordoba, Spain
[4] Fundacio Hosp Asil, Hematol, Granollers, Spain
[5] Inst Catala Oncol Duran & Reynals, Hematol, Barcelona, Spain
[6] Hosp Virgen de la Luz, Hematol, Cuenca, Spain
[7] Hosp Joan XXIII Tarragona, Hematol, Tarragona, Spain
[8] Hosp Univ La Fe, Hematol, Valencia, Spain
[9] Hosp del Mar, Hematol Cytol Lab, Barcelona, Spain
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30272-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
271
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [1] Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome
    Marcel Merchan, Brayan
    Ortega, Margarita
    Jose Llamas-Poyato, Mara
    Cortes, Montserrat
    Arnan, Montserrat
    Cervero, Carlos
    Montoro, Julia
    Gimenez, Teresa
    Lopez, Mara
    Arenillas, Leonor
    Valcarcel, David
    [J]. BLOOD, 2014, 124 (21)
  • [2] OUTCOMES OF CONTINUED AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME IN IPSS LOW AND INTERMEDIATE-1
    Moon, J. H.
    Sohn, S. K.
    Cho, Y. Y.
    Kim, Y. K.
    Kim, H. J.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. K.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Yeon, J. Deok
    [J]. HAEMATOLOGICA, 2012, 97 : 141 - 141
  • [3] Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Wang, Xuemei
    Abruzzo, Lynne V.
    Cornelison, A. Megan
    O'Brien, Susan
    Ravandi, Farhad
    Kadia, Tapan
    Borthakur, Gautam
    Estrov, Zeev
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2011, 118 (21) : 1624 - 1624
  • [4] The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome
    Papadaki, H.
    Mavroudi, I.
    Psyllaki, M.
    Pyrovolaki, K.
    Papadaki, V.
    Kalpadakis, C.
    Mastrodimou, S.
    Kaparou, M.
    Kanellou, P.
    Gvazava, G.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S47 - S48
  • [5] Improved survival rates with continued treatment with hypomethylating agents in patients with myelodysplastic syndrome in IPSS low and intermediate-1
    Moon, J.
    Sohn, S. K.
    Kim, Y. K.
    Kim, H. J.
    Lim, S. N.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. S.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Jo, D. Y.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S165 - S166
  • [6] PHASE 1 SAFETY OUTCOMES OF MESENCHYMAL STROMAL STEM CELL THERAPY IN PATEINTS WITH LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Cirillo, M.
    Carnley, B.
    Tan, P.
    Tan, D.
    Sturm, M.
    [J]. CYTOTHERAPY, 2018, 20 (05) : S31 - S31
  • [7] Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload
    Ivars, David
    Collado, Rosa
    Alguero, Carmen
    Carmen Tormos, M.
    Diaz, Laura
    Luis Garcia-Ghnenez, Jose
    Arrizabalaga, Beatriz
    Orero, Mayte
    Perez, Pedro
    Sanchez, Magdalena
    Angeles Ruiz, M.
    Yaguee, Nuria
    Sancho-Tello, Reyes
    Regadera, Ana
    Tormo, Mar
    Egea, Mercedes
    Vidal, Elena
    Enrique O'Connor, J.
    Saez, Guillermo T.
    Carbonell, Felix
    [J]. BLOOD, 2012, 120 (21)
  • [8] LONG TERM FOLLOW UP OF 5 PATIENTS TREATED WITH MESENCHYMAL STROMAL CELL IMMUNOMODULATORY THERAPY FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Tan, D.
    Carnley, B.
    Sturm, M.
    Cirillo, M.
    [J]. CYTOTHERAPY, 2024, 26 (06) : S40 - S40
  • [9] ELTROMBOPAG FOR THE TREATMENT OF THROMBOCYTOPENIA OF LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A PROSPECTIVE, RANDOMIZED, TRIAL
    Oliva, E.
    Santini, V.
    Zini, G.
    Palumbo, G.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M.
    Molteni, A.
    Sanpaolo, G.
    Liberati, A.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M.
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Raimondo, F.
    Leoni, P.
    Alimena, G.
    Fioritoni, G.
    Latagliata, R.
    Nobile, F.
    [J]. HAEMATOLOGICA, 2013, 98 : 456 - 456
  • [10] Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial
    Oliva, E. N.
    Santini, V.
    Zini, G.
    Palumbo, G. A.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M. T.
    Molteni, A.
    Sanpaolo, G.
    Liberati, M.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M. A. Aloe
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Di Raimondo, F.
    Leoni, P.
    Alimena, G.
    Latagliata, R.
    Nobile, F.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
12345